ENMD-1198

DB05959ExperimentalSmall molecule

Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.

Mechanism: ENMD-1198, a new chemical entity (NCE) based on a modified chemical structure of 2-methoxyestradiol (2ME2), is designed to decrease metabolism while retaining 2ME2's multiple mechanisms of action, including inducing apoptosis, disrupting microtubules, and inhibiting HIF-1 alpha. In preclinical studies, ENMD-1198 has been shown to be an orally active, antimitotic agent that leads to arrest of cell division and apoptosis in tumor cells. It also exerts antiangiogenic activity that further contributes to its overall antitumor effects.
Curator reviewed
Primary indication: Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.Curator reviewed
Formula / weight: C₂₀H₂₅NO₂ · 311.425 g/mol (avg)
Code names: IRC-110160

Resolves to

Compound

Structure

InChIKeyYQJWOUQGXATDAE-ACNBBOPNSA-NSMILESCOC1=C(C=C2CC[C@H]3[C@@H]4CC=C[C@@]4(C)CC[C@@H]3C2=C1)C(N)=O

Targets

What you can answer from here — as of March 06, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with ENMD-1198, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.